A new study reveals substantial efficiency gains

The pharmaceutical and biotechnology industries are at a crossroads. Escalating development costs, new modalities, increasing scientific and logistical demands, regulatory complexity, and mounting pressure to accelerate timelines are creating unprecedented challenges for drug developers.

The traditional reliance on multiple vendors to manage different aspects of development—from drug substance and drug product manufacturing to clinical research and clinical supply—further complicates the process.

Amid these obstacles, new research is shedding light on a more effective approach. This white paper explores findings from a recent study commissioned by Thermo Fisher Scientific and conducted by the Tufts Center for the Study of Drug Development.